China Pharma Holdings (CPHI) executive compensation, 2025 proxy

Zhilin Li, Chairman, Chief Executive Officer, President and interim Chief Financial Officer, was paid $316,000 in 2024, up 31% from $241,600 the year before.

Filed
November 14, 2025
Annual meeting
December 30, 2025
Pay year
2024
Named executives
1
CEO total pay
$316,000+31% vs prior year
CEO Salary
$300,000Fiscal year 2024
CEO Total Compensation
$316,000Fiscal year 2024
Prior Year CEO Total
$241,600Fiscal year 2023
Audit Fees
$125,000Paid to Enrome LLP

How Li was paid

$316,000 in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary95%All other compensation5%

Named executive officers

ExecutiveTotal
Zhilin LiChairman, Chief Executive Officer, President and interim Chief Financial Officer$316,000

What changed and why

  • $316KZhilin Li received a total compensation of $316,000 for fiscal year 2024, an increase from $241,600 in the prior year.
  • $300KThe CEO salary for 2024 was reported as $300,000 alongside $16,000 in all other compensation.
  • The operating subsidiary renewed an employment agreement with the CEO extending through December 31, 2029.
  • $125KAudit fees paid to Enrome LLP for fiscal year 2024 were approximately $125,000.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.